28th Oct 2021 21:59
Hutchmed (China) Ltd - Hong-Kong based pharmaceutical company - Begins phase 3 trial of HMPL-523 in patients suffering from immune thrombocytopenia, an autoimmune disease which increases risk of bleeding. "The first patient received their first dose on October 27, 2021," Hutchmed says.
Current stock price: 437.00 pence
Year-to-date change: down 5.0%
By Eric Cunha; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed